Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2021: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
Outline of Final Research Achievements |
Aiming to gain insight into the metabolic pathways of glycan metabolisms of which pathways are poorly understood, we performed gross glycomic analyses upon exposure of HepG2 cells to various glycan metabolism inhibitors of which inhibitory mechanisms are well understood (e.g. inhibitors of alpha-glucosidases, alpha-mannosidases, intracellular protein transport, sarco-endoplasmic reticulum Ca(2+)-ATPases, etc.). These analyses allowed to clarify the correlation between inhibitor employed and expression profile of glycans of which metabolic pathways are not fully understood.
|